Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The left ventricular assist device.

A Elaine Bond1, Karl Nelson, Cara Lynn Germany

  • 1College of Nursing, Brigham Young University, Provo, UT, USA. Elaine_Bond@BYU.edu

The American Journal of Nursing
|January 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venoarterial ECMO for Adults: JACC Scientific Expert Panel.

Journal of the American College of Cardiology·2019
Same author

Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities.

AJR. American journal of roentgenology·2017
Same author

Reply: To PMID 23694727.

Journal of minimally invasive gynecology·2013
Same author

Endometrial ablation: is tubal ligation a risk factor for hysterectomy.

Journal of minimally invasive gynecology·2013
Same author

Depression and caregiver burden experienced by caregivers of Jordanian patients with stroke.

International journal of nursing practice·2012
Same author

Who uses nursing theory? A univariate descriptive analysis of five years' research articles.

Scandinavian journal of caring sciences·2010

End-stage heart failure affects 400,000 Americans annually. Left ventricular assist devices (LVADs) offer a life-extending solution for patients unresponsive to traditional medical treatments.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • End-stage heart failure impacts a significant portion of the US population annually.
  • A substantial number of patients do not respond to conventional medical therapies for advanced heart failure.

Observation:

  • Approximately 400,000 individuals in the US develop end-stage heart failure each year.
  • Of these, 60,000 are refractory to medical management.
  • A small fraction, 2,500, receive heart transplants.

Findings:

  • Surgically implanted mechanical pumps, known as left ventricular assist devices (LVADs), are a critical intervention.
  • LVADs are demonstrably extending the lives of individuals with advanced heart failure.

Implications:

Related Experiment Videos

  • LVADs represent a vital therapeutic option for heart failure patients ineligible for transplantation.
  • The increasing use of LVADs signifies a shift in managing end-stage heart failure.
  • Further research into LVAD technology may improve outcomes and expand patient eligibility.